Sign up Australia
Proactive Investors - Run By Investors For Investors

Cellmid steps onto world stage for hair research in Japan

The three-day conference program begins Wednesday 1 November, 2017.
Audience listens to the speech of the lecturer in the conference hall
The forum is attended by over 700 leading international scientists and clinicians

Cellmid (ASX:CDY) will be presenting the recently published FGF5 inhibitor clinical data at the World Congress for Hair Research in Kyoto, Japan.

Dr Dominic Burg will be presenting the results of the recently published clinical study describing the efficacy of the FGF5 inhibiting évolis® tonic formulation.

The talk will be given on the first day and in front of the entire congress, making it one of the most significant presentations during the three days of proceedings.

Key findings of the recently published clinical study demonstrated that topical use of évolis® was effective against hair loss in men and women.

Over 16 weeks of treatment évolis®:

- Reduced hair loss by 82%;
- Increased the rate of actively growing hair follicles by 44%; and
- Improved hair density.

World Congress for Hair Research

The World Congress for Hair Research is the preeminent scientific meeting for hair science, organised by several international organisations including The Society for Hair Science Research and the North American Hair Research Society.

The congress is attended by more than 700 hair biologists, dermatologists, cosmetic scientists and hair transplantation surgeons from over 50 countries.

The presentation of results on the use of Advangen’s FGF5 inhibiting topical formulation to such an internationally recognised expert audience will provide an excellent avenue for exposure of the company’s technology, compelling clinical data and products.

A second abstract on the Cellmid’s FGF5 technology will be presented in the form of a scientific poster, a common occurrence at the conference.


Cellmid has two business segments - consumer health and its midkine (MK) portfolio.

The consumer health segment currently sells hair growth products in Australia, Japan and the U.S, which were developed using FGF5 related intellectual property.

During the recent September quarter, the consumer health segment achieves sales of $1.03 million, up 4% on the prior corresponding quarter.

The majority of sales are generated in Japan and Cellmid most recently launched its lead revenue driving évolis® hair loss products into the U.S. market.

Cellmid finished the September quarter with circa $2.9 million in cash, which didn’t include the $0.95 million tax credit received in early October.

The company recently opened its first Advangen Hair Biology concept store in Tokyo, Japan.

READ NOW: Cellmid lifts revenue options after taking clinically validated hair products to Tokyo

View full CDY profile View Profile

Cellmid Ltd Timeline

Related Articles

lupus poster
January 18 2018
The last of the 200 patients has had their final assessment and the data is now being processed and analysed
December 18 2017
VAL201 is a treatment for metastatic prostate cancer and other solid tumours
September 27 2017
The firm received an order for its clinical research use only (RUO) kits from a large, multinational pharma company

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use